Roundtable Roundup: First and Second Choices for Frontline RCC Therapy
During separate virtual live events, David A. Braun, MD, PhD, and Rana R. McKay, MD, surveyed oncologists on options for a patient with clear cell renal cell carcinoma (RCC) in the front line.
GU Oncologists Anticipate Earlier Role of Lutetium-177 PSMA-617 in Prostate Cancer
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.
Lipsky Discusses Second-Generation BTK Inhibitors in Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with chronic lymphocytic leukemia.
Sardesai Discusses ADC Selection Based on HR and HER2 Status in mBC
During a Case-Based Roundtable® event, Sagar D. Sardesai, MD, moderated a discussion on using antibody-drug conjugates and managing their toxicities in patients with metastatic breast cancer.
